Article
Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19*2 genotype?
European journal of clinical pharmacology - 1 Dec 2018
Chouchene Saoussen, Dabboubi Rym, Raddaoui Haythem, Abroug Hela, Ben Hamda Khaldoun, Hadj Fredj Sondess, Abderrazak Fatma, Gaaloul Mayssa, Rezek Marwa, Neffeti Fadoua, Hellara Ilhem, Sassi Mouna, Khefacha Linda, Sriha Asma, Nouira Semir, Najjar Mohamed Fadhel, Maatouk Faouzi, Messaoud Taieb, Hassine Mohsen
Abstract excerpt
PURPOSE: Clopidogrel non-responsiveness is multifactorial; several genetic and non-genetic factors may contribute to impaired platelet inhibition. The goal of this study is to determine the effect of the cytochrome P450 CYP2C19*2 polymorphism on the platelet response to clopidogrel in patients with and without diabetes mellitus (DM). METHODS: We conducted an observational study in patients with coronary artery...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.